---
title: Cell and Gene Therapy Catapult vs SCTbio
slug_a: ct
slug_b: sctbio
site: cdmo
review_signal_gate: closed
canonical_path: /compare/ct/sctbio
generated_by: BioBM Editorial AI
---

# Cell and Gene Therapy Catapult vs SCTbio

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Cell and Gene Therapy Catapult (ct) is listed for cdmo. UK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.

Services: 13. Modalities: 3. Indications: 4. Locations: 5. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (13).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

SCTbio (sctbio) is listed for cdmo. SCTbio is a European cell and gene therapy CDMO offering cGMP manufacturing, lentiviral and gammaretroviral vector production, analytical development, and QP batch release. Its facilities include 420 m² of Class A/B/C GMP cleanrooms, and it reports more than 2,000 GMP batches manufactured.

Services: 10. Modalities: 2. Indications: 1. Locations: 2. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (10).

Review summary: Review summary withheld until site-level review gate opens.